Allovir IncNASDAQ:ALVRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8300
- TODAY'S CHANGE (%)0.0050 (0.6061%)
- Bid / Lots0.8106/ 9
- Ask / Lots0.8349/ 15
- Open / Previous Close0.8300 / 0.8250
- Day Range
- 52 Week Range
- Volume482
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALVR |
|---|---|---|
| 09:32 ET | 173 | 0.83 |
Sep 16, 2024
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm, from 11:16AM ET on Monday Sep 16, 2024 by Dow Jones
11:16AM ET on Monday Sep 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allovir Inc | 95.2M | -0.7x | --- |
Fibrobiologics Inc | 94.2M | -2.9x | --- |
ALX Oncology Holdings Inc | 96.4M | -0.5x | --- |
Leap Therapeutics Inc | 93.7M | -1.2x | --- |
Tiziana Life Sciences Ltd | 96.8M | -5.9x | --- |
Citius Oncology Inc | 92.7M | 5.5x | --- |
Company Information
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Contact Information
- Headquarters
- 1100 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 617-433-2605
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- David Hallal
- President, Chief Financial Officer, Director
- Vikas Sinha
- Chief Executive Officer, Director
- Diana Brainard
- Co-Founder, Chief Scientific Officer
- Ann Leen
- Chief Accounting Officer
- Brett Hagen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $95.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 115.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-1.23 |
Book Value | $1.28 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
